Harrow (HROW) | Stock Overview & Key Data
Harrow Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $140.00 on October 1, 2007
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Harrow
HROW
|
1.44B Small-cap | 17.61% | 24.74% | 11.52% | -14.81% | -22.00% | 24.18% | 101.50% | 351.86% | 903.73% | 572.14% | -68.63% |
|
Zoetis
ZTS
|
49.75B Large-cap | 0.16% | 3.42% | -31.08% | -32.94% | -36.81% | -51.58% | -53.40% | -57.08% | 71.34% | 156.59% | 156.59% |
|
Haleon Plc - ADR
HLN
|
42.40B Large-cap | 2.02% | 1.23% | -13.29% | -7.73% | -9.30% | -16.01% | 8.43% | 23.21% | 23.21% | 23.21% | 23.21% |
|
Dynavax Technologies
DVAX
|
1.82B Small-cap | 0.13% | -1.15% | 40.40% | 47.90% | 0.78% | 20.90% | 39.64% | 53.92% | -21.40% | -49.68% | -74.59% |
|
Ani Pharmaceuticals
ANIP
|
1.78B Small-cap | 2.70% | 5.49% | 14.02% | 0.96% | 4.92% | 30.56% | 59.07% | 147.74% | 54.58% | -9.96% | 3.13% |
|
Perrigo Company plc
PRGO
|
1.61B Small-cap | -7.84% | 0.85% | 10.08% | -16.67% | -22.97% | -58.76% | -68.05% | -76.25% | -88.79% | -86.87% | -34.15% |
Ownership & Short Interest
Calculate Your Harrow Investment Returns
Long-Term Investment Performance Analysis
Harrow stock price in Jul 2016 was $4.07, A $1,000.00 lump sum investment in Harrow made 9 years ago would be worth approximately $9,565.11 today, representing a exceptional return of 856.51%. This translates to an annualized return (CAGR) of 25.60%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is HROW's 52-week high and low?
- In the last 52 weeks, Harrow reached a high of $54.85 (on January 7, 2026) and a low of $28.54 (on May 13, 2026).
- What is the market cap and P/E ratio for HROW?
- Curious about Harrow's size and valuation? Its market capitalization stands at 1.44B. When it comes to valuation, the P/E ratio (trailing twelve months) is -277.07, and the forward P/E (looking ahead) is 14.39.
- Does HROW pay dividends? If so, what's the yield?
- As for dividends, Harrow isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Harrow's main competitors or similar companies to consider before investing?
When looking at Harrow, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Zoetis
ZTS49.75B Healthcare Drug Manufacturers - Specialty & Generic -51.58% -53.40% Haleon Plc - ADR
HLN42.40B Healthcare Drug Manufacturers - Specialty & Generic -16.01% 8.43% Dynavax Technologies
DVAX1.82B Healthcare Drug Manufacturers - Specialty & Generic 20.90% 39.64% Ani Pharmaceuticals
ANIP1.78B Healthcare Drug Manufacturers - Specialty & Generic 30.56% 59.07% Perrigo Company plc
PRGO1.61B Healthcare Drug Manufacturers - Specialty & Generic -58.76% -68.05% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Harrow Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Harrow's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -8.47%, the Debt to Equity ratio from the most recent quarter is 483.72, and its Gross Profit Margin stands at 79.27%.
- What is the recent revenue and earnings growth for HROW?
- Looking at Harrow's growth, its revenue over the trailing twelve months (TTM) was $272M. Compared to the same quarter last year (YoY), quarterly revenue grew by 33.30%, and quarterly earnings saw a YoY growth of -2.20%.
- How much of HROW stock is held by insiders and institutions?
- Wondering who owns Harrow stock? Company insiders (like executives and directors) hold about 16.14% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 60.75%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.